enGene Therapeutics Inc. has recently submitted a Form 3, revealing that Chief Legal & Admin Officer Jason Duncan holds no securities ownership in the company. This filing is significant as it underscores the company's commitment to transparency and regulatory compliance.

enGene Therapeutics Inc. operates in the biological products sector, specifically classified under SIC 2836, which includes companies engaged in the development and production of biological products, excluding diagnostic substances. The company trades on the Nasdaq under the ticker symbols ENGN and ENGNW.

The filing indicates that as of November 9, 2026, Duncan had no beneficial ownership of securities. The document states, "No securities beneficially held" and confirms that he does not own any shares following this transaction.

This disclosure may affect various stakeholders, including current and potential investors, who rely on such filings to assess the company's governance and transparency. It also serves as a reminder for other companies in the biological products sector to maintain clear and accurate reporting practices.

The filing does not specify any further actions or upcoming events related to this disclosure.

Details of Reporting Owner

The filing identifies Jason Duncan as the reporting owner, confirming his role as the Chief Legal & Admin Officer of enGene Therapeutics Inc. It also clarifies that he is not a director and does not hold a ten percent ownership stake in the company. His address is listed as 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, which indicates that he is associated with the company's operations outside of the United States.

Limited Power of Attorney

Additionally, the filing includes a Limited Power of Attorney, executed on November 12, 2026, which grants authority to Kathleen Richton, Jason Catherman, and Elizabeth Shortsleeve to act on Duncan's behalf regarding the filing of Forms 3, 4, and 5 under Section 16(a) of the Securities Exchange Act of 1934. This provision allows these individuals to manage the reporting obligations related to securities transactions, ensuring compliance with regulatory requirements.

"The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act."

Company Background

enGene Therapeutics Inc. was formerly known as enGene Holdings Inc., with the name change officially recorded on June 8, 2023. The company operates under the classification of biological products, focusing on innovative therapeutic solutions, which positions it within a competitive and rapidly evolving sector.